SYUMIX | Syntax US Medical Innovation Index

Index Description

The Syntax US Medical Innovation Index comprises up to 50 equally weighted US-listed companies engaged in the biotechnology and biopharma industry. The Index's universe of companies is maintained with the help of company classification data structured in Syntax's proprietary Functional Information System (FIS), which draws primarily from audited annual reports (e.g., SEC Form 10-K filings) and secondarily from unaudited documents (e.g., investor presentations, company websites, news articles) to allow granular groupings and comparisons of companies by the characteristics of their various product lines. To qualify, a company must pass the Index's screens for size and liquidity, and must own at least one drug that is in an FDA Phase II or Phase III trial and has a special FDA designation or a milestone in the near future.

Index Facts

Number of Constituents 49
Weighting Methodology Equal
Rebalancing Frequency Quarterly
Currency USD
Exchange Symbol/Ticker SYUMIX
Index Inception Date October 21, 0202
Total Return Index Value as of 12/13/2023 1122.47

Index Performance

Multi-Horizon Returns % as of 2023-09-30
YTD3Q231Y3Y5Y7Y10YSince 10.21.22
US Medical Innovation-9.78-8.29------7.26
Top Holdings as of 2023-09-30
Click on a company name to view more information on key statistics, classification and more. Premium data requires an Affinity login.
Company Weight (%)
Intercept Pharmaceuticals Inc 3.71
Crinetics Pharmaceuticals Inc 3.30
Rhythm Pharmaceuticals Inc 3.25
HUTCHMED (China) Ltd 2.96
CymaBay Therapeutics Inc 2.91
Teva Pharmaceutical Industries ADR 2.81
Mirati Therapeutics Inc 2.78
Insmed Inc 2.77
Mirum Pharmaceuticals Inc 2.72
Ardelyx Inc 2.71